Disclosed is a pharmaceutical composition comprised of one SGLT-2 inhibitor compound in combination with a second therapeutic agent which is suitable for the treatment of one or more metabolic disorders wherein i) said one SGLT-2 inhibitor compound is the glucopyranosyl-substituted benzene derivative: l-chloro-4-(8-D-glucopyranos-l-yl)-2-[ 4-((S)-tetrahydrofuran-3-yloxy)benzyl]- benzene; and ii) said second therapeutic agent which is suitable for the treatment of one or more metabolic disorders ...

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug and metformin XR processes for the preparation thereof and their use to treat certain diseases.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug and metformin XR processes for the preparation thereof and their use to treat certain diseases.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug and metformin XR processes for the preparation thereof and their use to treat certain diseases.

ABSTRACT - 591008 The disclosure relates to the use of a DPP-4 inhibitor such as 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine which is represented by either of the formulae (I) (II) (III) or (IV) and pharmaceutically acceptable salt wherein the variables are as defined in the specification. These compounds are suitable for wound healing preferably in diabetic patients or for reducing destructive wound inflammation such as e.g. for reducing...

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug and metformin XR processes for the preparation thereof and their use to treat certain diseases.

Disclosed is a pharmaceutical composition which comprises or is made from a DPP-IV inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine free base (BI-1356) a partner drug which is metformin hydrochloride one or more pharmaceutical excipients and a nucleophilic and/or basic agent and/or buffering agent (such as L-arginine L-lysine and L-histidine) for stabilizing said DPP-4 inhibitor against degradation. Further disclosed is a s...

Disclosed herein is the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine which is a DPP-4 inhibitor or a pharmaceutically acceptable salt thereof for preparing a medicament for oral administration for treating and/or preventing of metabolic diseases in patients for whom metformin therapy is inappropriate due to contraindication against metformin. Said medicament may be used in the treatment and/or prevention of type 2 diabetes mellitus...